Becker Y
Department of Molecular Virology, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Acta Biochim Pol. 1996;43(1):175-81.
The analysis of the history of the research on antivirals especially the treatment of HIV-1 infected individuals with antivirals which were developed prior to the current AIDS epidemic led to suggest a different approach to the targeting of antivirals in the AIDS patients. Since HIV-1 replication in infected individuals occurs in the lymph nodes, it is suggested that modified anti-HIV-1 drugs should be applied to Langerhans cells in the skin. The Langerhans cells can serve as the carries of the antiviral drugs attached to their surfaces due to their ability to migrate from the skin through the lymph vessels and to home to the lymph node. At that site Langerhans cells interact with T cells. Transfer of the anti-HIV-1 drugs to infected CD4+ T cells in the lymph node will reduce virus replication in the lymph nodes and will reduce the cytotoxic systemic effects of the antiviral drug. Such an antiviral treatment requires the development of efficient methods of drug delivery through the skin.
对抗病毒药物研究历史的分析，尤其是对当前艾滋病流行之前研发的抗病毒药物治疗HIV-1感染者的分析，促使人们提出一种针对艾滋病患者使用抗病毒药物的不同方法。由于HIV-1在受感染个体中的复制发生在淋巴结中，因此有人建议应将经过改良的抗HIV-1药物应用于皮肤中的朗格汉斯细胞。朗格汉斯细胞能够从皮肤通过淋巴管迁移并归巢至淋巴结，因此可作为附着在其表面的抗病毒药物的载体。在该部位，朗格汉斯细胞与T细胞相互作用。将抗HIV-1药物转移至淋巴结中受感染的CD4+ T细胞，将减少淋巴结中的病毒复制，并降低抗病毒药物的细胞毒性全身效应。这种抗病毒治疗需要开发通过皮肤进行有效给药的方法。
